Hinge Health says revenue increased 50% in first quarter — still no price range for IPO

Hinge Health says revenue increased 50% in first quarter — still no price range for IPO


Hinge Health’s TrueMotion feature.

Courtesy: Hinge Health

Hinge Health on Monday updated its prospectus to include the results from its first quarter, which showed accelerating revenue growth over its fourth quarter.

The digital physical therapy startup filed to go public in March, but it has not shared a price range yet. Hinge said that revenue in its first quarter climbed 50% to $123.8 million, up from $82.7 million during the same period last year. Hinge reported $117.3 million in revenue during its fourth quarter, up 44% from the same period in 2023.

Hinge also notched its first profitable quarter on record. The company said its net income for the period was $17.1 million after taxes, up from a net loss of $26.5 million after taxes during the same period last year.

The company is attempting to go public at a time of extreme economic uncertainty and market volatility, spurred largely by President Donald Trump’s sweeping tariff policy. Several companies, including online lender Klarna and ticket marketplace StubHub, have delayed their long-awaited IPOs.

Hinge’s updated prospectus signals to investors that the company is planning to forge ahead.

More CNBC health coverage

While the company’s revenue jumped 50%, the cost of goods sold fell slightly. That allowed Hinge to lift its gross margin to 81% from 70% a year earlier and record an operating income of $13.1 million after losing $31. 4 million in the same period a year earlier.

Hinge uses software to help patients treat acute musculoskeletal injuries, chronic pain and carry out post-surgery rehabilitation remotely. Large employers cover the costs so their employees can access Hinge’s app-based virtual physical therapy, as well as its wearable electrical nerve stimulation device called Enso. 

Daniel Perez, Hinge’s CEO, and Gabriel Mecklenburg, the company’s executive chairman, co-founded the company in 2014 after experiencing personal struggles with physical rehabilitation.



Source

Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms 
Health

Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms 

US President Donald Trump speaks during a cabinet meeting in the Cabinet Room of the White House in Washington, DC, on April 30, 2025. Jim Watson | Afp | Getty Images President Donald Trump on Monday signed an executive order to incentivize drug manufacturing in the U.S., streamlining the path for pharmaceutical companies to build […]

Read More
CVS to boost access to Novo Nordisk’s weight loss treatment Wegovy for patients on its drug plans
Health

CVS to boost access to Novo Nordisk’s weight loss treatment Wegovy for patients on its drug plans

The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images CVS Health on Thursday said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its […]

Read More
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
Health

Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal

Eli Lilly on Thursday reported first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs soared, but lowered its full-year profit guidance due to charges related to a recent cancer treatment deal. The pharmaceutical giant now expects its adjusted fiscal 2025 earnings to come in between $20.78 and $22.28 […]

Read More